Subbian et al. (2021) reported similar findings for RET-variant MTC patients using a pralsetinib treatment regimen, as 60% of formerly treated patients experienced a response and 71% of patients without prior treatment experienced a response. This evidence concerns the gene RET and medullary thyroid gland carcinoma.